

## Opinion on polycystic ovarian syndrome and infertility

Kristofina Williams

---

Kristofina W. Opinion polycystic ovarian syndrome and infertility. J Reprod Biol Endocrinol. 2022; 6(1):1

---

### OPINION

Polycystic Ovary Syndrome (PCOS) is a heterogeneous endocrine syndrome with variable prevalence, affecting about one in every 17 women worldwide. The diagnosis of polycystic ovary syndrome requires as a minimum two of the following criteria: anovulation, clinical, biochemical evidence of hyperandrogenism and morphology of polycystic ovaries. Women with PCOS appear to have a higher risk of developing metabolic syndromes, hypertension and cardiovascular disorders.

Public awareness of PCOS is necessary because over half of the 10,000,000 people that have it, are unaware of it. Awareness helps the public understand that symptoms like irregular periods and pelvic pain are not something to be ignored and getting it checked is necessary.

PCOS 2022 deals with Polycystic and Ovarian Syndrome knowledge and characteristics, Screening, Detecting and Diagnosing PCOS, Fertility issues, Treatment, prevention and medicine. The correct reason for PCOS is obscure. For the most part, it is a hormonal issue normal among ladies of regenerative age. Ladies with PCOS may have inconsistent or drawn out menstrual periods or overabundance male hormone (androgen) levels. Awareness about the risks, symptoms and treatment is very important. Introduction of new techniques in the field of medicine as well as diagnosis is going on worldwide. PCOS 2022 give a stage to sharing of data about the PCOS treatment methods and recently created strategies for the same and in addition give stage about the on-going examines on it. This occasion incorporates incite keynote introductions, oral talks, blurb introductions and displays.

### Statistics which shows Market growth in importance of research of PCOS

PCOS is the commonest cause of an ovulatory infertility in women. Women may also suffer from cancer of the womb, obesity, cardiovascular disease, diabetes and hirsutism. It affects 6-20% of

*Managing Editor, Journal of Reproductive Biology and Endocrinology, UK*

women in the population and the current expected annual costs of diagnosing and treating infertility secondary to PCOS in the UK range from £15million to £20 million whereas the health economic effect of PCOS in the USA effects 10%-20% and has been estimated as ranging from \$93 million to \$1.77 billion. Although important progress has been made in our understanding of PCOS, there are still challenges in unraveling its difficulty. The analysis of PCOS is based on a combination of clinical, ultrasound and biochemical features, none of which on its own is diagnostic single unifying mechanism has yet to be found which explains PCOS, and accurate prediction of response to treatment for obesity, infertility.

Worldwide Data evaluations that the global PCOS therapeutics market was valued at \$656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach \$804m by 2018. Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Polycystic Ovarian Syndrome Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018. according to PCOS Therapeutics market revenue, the market size from 2005-2010 in Italy is 33, USA is 26, Spain is 35, in France 28, whereas in Germany is 31, whereas in UK is 37 whereas from 202-2018 in Italy is 34, in us is 27, Spain is 36, in France is 29, in Germany is 32, whereas in UK is 38. The Polycystic Ovarian Syndrome Market Will Start Growing From 2013 Due To the Increase in Disease Prevalence and Prescription Rates and Will Rise to \$702m In 2019. The global market for PCOS drugs is on an upward swing given the increasing number of cases of patients inflicted with the disease. The global polycystic ovary syndrome drugs market revenue is estimated to reach US\$ 1,154.8 MN by 2024, expanding at a CAGR of 4.6% during the forecast period (2016-2024).

---

Correspondence: Kristofina Williams, Managing Editor, Journal of Reproductive Biology and Endocrinology, UK. E-mail- [medicine@emedicinejournals.org](mailto:medicine@emedicinejournals.org)

Received:- 03 January, 2022, Manuscript No. M- PULJRBE-22-4681; Editor assigned:- 05 January, 2022, Pre-QC No. PULJRBE-22-4681(PQ); Reviewed:- 13 January, 2022, QC No. PULJRBE-22-4681(Q); Revised:- 17 January, 2022, Manuscript No. PULJRBE-22-4681 (R); Published:- 21 January, 2022, DOI: 10.37532.2022.6.(1)1



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [reprints@pulsus.com](mailto:reprints@pulsus.com)